Organon & Co. (OGN)

$7.14 -0.13 (-1.79%)
Market Cap 1.95B
Revenue (ttm) 6.40B
Net Income (ttm) 864.00M
EPS (ttm) N/A
PE Ratio 2.05
Forward PE 2.07
Profit Margin 13.49%
Debt to Equity Ratio 9.74
Volume 3,178,286
Avg Vol 6,017,640
Day's Range N/A - N/A
Shares Out 259.98M
Stochastic %K 21%
Beta 0.57
Analysts Hold
Price Target $10.33

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
AtomicAIerts
AtomicAIerts Dec. 5 at 9:07 AM
$OGN AtomicAlerts Scalp Alert Direction: SHORT Entry: $7.14 TP1: $6.44 | TP2: $5.74 | TP3: $5.04 Stop Loss: $7.74 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 4:39 AM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $7C Entry: 0.45 Exit: 0.55 Return: +21.62% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 10:27 PM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $7C Entry: 0.45 Exit: 0.55 Return: +21.62% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:08 AM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $6C Entry: 1.02 Exit: 1.68 Return: +63.85% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 12:24 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $OGN **Contract:** Dec 19 $7C **Entry:** 0.92 **Exit:** 1.47 **Return:** **+59.76% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
resistancebreakers
resistancebreakers Nov. 28 at 10:06 AM
$OGN Interesting asset. They're going to do a presentation to Piper Sandler next week 📡🪖🫡☝️
1 · Reply
Iightning
Iightning Nov. 26 at 3:17 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:21 PM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
MrNotSoNice
MrNotSoNice Nov. 25 at 5:07 AM
$OGN Adding 🧐📈💰💊
0 · Reply
Iightning
Iightning Nov. 25 at 2:15 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
Latest News on OGN
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 12:23 PM EST - 1 day ago

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 9 days ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 17, 2025, 5:30 AM EST - 18 days ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Nov 11, 2025, 12:58 PM EST - 23 days ago

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Organon Analysts Cut Their Forecasts Following Q3 Results

Nov 11, 2025, 11:40 AM EST - 23 days ago

Organon Analysts Cut Their Forecasts Following Q3 Results

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:51 AM EST - 24 days ago

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 10, 2025, 7:30 AM EST - 24 days ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 7, 2025, 7:30 AM EST - 27 days ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Oct 28, 2025, 2:06 PM EDT - 5 weeks ago

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Oct 27, 2025, 6:22 PM EDT - 5 weeks ago

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:44 AM EDT - 5 weeks ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 27, 2025, 7:30 AM EDT - 5 weeks ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Oct 17, 2025, 7:10 AM EDT - 6 weeks ago

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 19, 2025, 6:00 AM EDT - 2 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 3 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon: Valuation Discount Offset By Structural Headwinds

Aug 12, 2025, 2:22 PM EDT - 4 months ago

Organon: Valuation Discount Offset By Structural Headwinds

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 6, 2025, 11:59 AM EDT - 4 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Organon (OGN) Fiscal Q2 Revenue Beats 1%

Aug 6, 2025, 2:47 AM EDT - 4 months ago

Organon (OGN) Fiscal Q2 Revenue Beats 1%

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:10 PM EDT - 4 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Organon Reports Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 22, 2025, 7:30 AM EDT - 4 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 21, 2025, 4:02 PM EDT - 4 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 20, 2025, 10:55 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 5 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 5 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 7, 2025, 7:30 AM EDT - 5 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 8:25 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Karolinska Development receives update from Organon concerning OG-6219

Jul 3, 2025, 1:00 AM EDT - 5 months ago

Karolinska Development receives update from Organon concerning OG-6219

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 8:01 AM EDT - 5 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jul 2, 2025, 7:30 AM EDT - 5 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 28, 2025, 7:46 AM EDT - 5 months ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 26, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 20, 2025, 9:06 AM EDT - 5 months ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Jun 18, 2025, 8:38 AM EDT - 6 months ago

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Organon: A Look Beyond The Dividend Cut

Jun 18, 2025, 1:02 AM EDT - 6 months ago

Organon: A Look Beyond The Dividend Cut

AtomicAIerts
AtomicAIerts Dec. 5 at 9:07 AM
$OGN AtomicAlerts Scalp Alert Direction: SHORT Entry: $7.14 TP1: $6.44 | TP2: $5.74 | TP3: $5.04 Stop Loss: $7.74 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 4:39 AM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $7C Entry: 0.45 Exit: 0.55 Return: +21.62% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 10:27 PM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $7C Entry: 0.45 Exit: 0.55 Return: +21.62% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:08 AM
1ightning® Premium Options Alert (Actionable) Ticker: $OGN Contract: Dec 19 $6C Entry: 1.02 Exit: 1.68 Return: +63.85% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 12:24 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $OGN **Contract:** Dec 19 $7C **Entry:** 0.92 **Exit:** 1.47 **Return:** **+59.76% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
resistancebreakers
resistancebreakers Nov. 28 at 10:06 AM
$OGN Interesting asset. They're going to do a presentation to Piper Sandler next week 📡🪖🫡☝️
1 · Reply
Iightning
Iightning Nov. 26 at 3:17 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:21 PM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
MrNotSoNice
MrNotSoNice Nov. 25 at 5:07 AM
$OGN Adding 🧐📈💰💊
0 · Reply
Iightning
Iightning Nov. 25 at 2:15 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.12 Exit: $0.23 | Profit: 94.16% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 11:31 PM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.41 Exit: $0.54 | Profit: 31.46% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 2:50 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.41 Exit: $0.54 | Profit: 31.46% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 12:14 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.41 Exit: $0.54 | Profit: 31.46% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 8:28 AM
1ightning® Options Trade Alert (Actionable) | Buy $OGN Dec 19 $8 Call | Enter: $0.41 Exit: $0.54 | Profit: 31.46% ROI | https://1ightning.com
0 · Reply
trader2360
trader2360 Nov. 17 at 4:47 PM
$OGN
0 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Nov. 17 at 4:39 PM
$OGN it'll pop eventually
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Nov. 17 at 10:43 AM
$OGN Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
1 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Nov. 12 at 4:56 PM
$OGN if we get above 7.77 we fill the gap to around 9
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:09 PM
JP Morgan has adjusted their stance on Organon ( $OGN ), setting the rating to Underweight with a target price of 14 → 12.
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 12:35 PM
Morgan Stanley updates rating for Organon ( $OGN ) to Equal-Weight, target set at 10 → 9.
0 · Reply
epetes
epetes Nov. 11 at 12:10 AM
$OGN I sold at 7.75 today for an excellent 2 week profit from 6.50. I set a limit to buy back at 7.35 and ride it up again.
0 · Reply
GSP
GSP Nov. 11 at 12:10 AM
$SPY $SNAP $LWLG $OGN $ASST
0 · Reply